Drug Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage Following Aneurysms

α
Yong-Fei Liu
Yong-Fei Liu
σ
Han-Cheng Qiu
Han-Cheng Qiu
ρ
Juan Su
Juan Su
Ѡ
Wei-Jian Jiang
Wei-Jian Jiang
α Army Medical University

Send Message

To: Author

Drug Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage Following Aneurysms

Article Fingerprint

ReserarchID

3W89X

Drug Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage Following Aneurysms Banner

AI TAKEAWAY

Connecting with the Eternal Ground
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu

Abstract

Cerebral vasospasm (CVS) is a common and severe complication of aneurysmal subarachnoid hemorrhage (aSAH). Despite the improvement in treatment of aSAH, CVS complicating aSAH has remained the main cause of death. CVS begins most often on the third day after the ictal event and reaches the maximum on the 5th-7th postictal days. Several therapeutic modalities have been employed to prevent or reverse CVS. The aim of this review is to emphatically introduce some kind of pharmacological agent for vasospasm.

References

59 Cites in Article
  1. Joshua Bederson,E Connolly,H Batjer,Ralph Dacey,Jacques Dion,Michael Diringer,John Duldner,Robert Harbaugh,Aman Patel,Robert Rosenwasser (2009). Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage.
  2. C Lovelock,G Rinkel,P Rothwell (2010). Time trends in outcome of subarachnoid hemorrhage: Populationbased study and systematic review.
  3. Y Murayama,T Malisch,G Guglielmi,M Mawad,F Vinuela,G Duckwiler (1997). Incidence of cerebral vasospasm after endovascular treatment of acutely ruptured aneurysms: Report on 69 cases.
  4. K Yalamanchili,R Rosenwasser,J Thomas,K Liebman,C Mcmorrow,P Gannon (1998). Frequency of cerebral vasospasm in patients treated with endovascular occlusion of intracranial aneurysms.
  5. C Charpentier,G Audibert,F Guillemin,T Civit,X Ducrocq,S Bracard (1999). Multivariate analysis of predictors of cerebral vasospasm occurrence after aneurysmal subarachnoid hemorrhage.
  6. Salah Keyrouz,Michael Diringer (2007). Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage.
  7. D Castanares-Zapatero,P Hantson (2011). Pharmacological treatment of delayed cerebral ischemia and vasospasm in subarachnoid hemorrhage.
  8. G Velat,M Kimball,J Mocco,B Hoh (2011). Vasospasm after aneurysmal subarachnoid hemorrhage: Review of randomized controlled trials and meta-analyses in the literature.
  9. Amanda Raya,Michael Diringer (2014). Treatment of Subarachnoid Hemorrhage.
  10. Alejandro Rabinstein,Giuseppe Lanzino,Eelco Wijdicks (2010). Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage.
  11. M Mackenzie,S Gorman,S Doucette,R Green (2014). Incidence of and factors associated with manipulation of nimodipine dosage in patients with aneurysmal subarachnoid hemorrhage.
  12. D Hänggi,J Perrin,S Eicker,K Beseoglu,N Etminan,M Kamp (2012). Local delivery of nimodipine by Prolonged-Release microparticles-feasibility, effectiveness and Dose-Finding in experimental subarachnoid hemorrhage.
  13. S Ott,S Jedlicka,S Wolf,M Peter,C Pudenz,P Merker (2014). Continuous selective intra-arterial application of nimodipine in refractory cerebral vasospasm due to aneurysmal subarachnoid hemorrhage.
  14. Erik Kronvall,Per Undrén,Bertil Romner,Hans Säveland,Mats Cronqvist,Ola Nilsson (2009). Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration.
  15. M Onal,E Civelek,A Kircelli,I Solmaz,S Ugurel,F Narin (2011). Comparison of nimodipine delivery routes in cerebral vasospasm after subarachnoid hemorrhage: An experimental study in rabbits.
  16. F Wang,Y Yin,F Jia,J Jiang (2013). Effects of Topical Administration of Nimodipine on Cerebral Blood Flow following Subarachnoid Hemorrhage in Pigs.
  17. B Hoh,C Ogilvy (2005). Endovascular treatment of cerebral vasospasm: Transluminal balloon angioplasty, intra-arterial papaverine, and intraarterial nicardipine.
  18. Ren-Qiang Huang,Fu-Gang Jiang,Zi-Min Feng,Tian-Yi Wang (2013). Nicardipine in the treatment of aneurysmal subarachnoid haemorrhage: a meta-analysis of published data.
  19. P Jun,N Ko,J English,C Dowd,V Halbach,R Higashida,M Lawton,S Hetts (2010). Endovascular Treatment of Medically Refractory Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage.
  20. R Stuart,R Helbok,P Kurtz,M Schmidt,L Fernandez,K Lee (2011). High-dose intra-arterial verapamil for the treatment of cerebral vasospasm after subarachnoid hemorrhage: Prolonged effects on hemodynamic parameters and brain metabolism.
  21. A Flexman,C Ryerson,P Talke (2012). Hemodynamic stability after intraarterial injection of verapamil for cerebral vasospasm.
  22. K Mikeladze,S Eliava,O Shekhtman,A Lubnin,T Tabasaranskii,S Iakovlev (2013). Intra-arterial injection of verapamil in treatment of cerebral vasospasm in a patient with acute subarachnoid hemorrhage from an aneurysm: Case report.
  23. J Keuskamp,R Murali,K Chao (2008). High-dose intraarterial verapamil in the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
  24. Carl Muroi,Martin Seule,Kenichi Mishima,Emanuela Keller (2012). Novel treatments for vasospasm after subarachnoid hemorrhage.
  25. Clemens Schirmer,Daniel Hoit,Adel Malek (2008). Iatrogenic vasospasm in carotid artery stent angioplasty with distal protection devices.
  26. J Liu,G Yao,H Zhou,X Jiang,P Xie (2014). Clinical investigation of fasudil for the prevention of cerebral vasospasm in extracranial carotid artery stenting.
  27. S Satoh,M Takayasu,K Kawasaki,I Ikegaki,A Hitomi,K Yano (2012). Antivasospastic effects of hydroxyfasudil, a Rho-Kinase inhibitor, after subarachnoid hemorrhage.
  28. M Naraoka,A Munakata,N Matsuda,N Shimamura,H Ohkuma (2013). Suppression of the Rho/Rho-kinase pathway and prevention of cerebral vasospasm by combination treatment with statin and fasudil after subarachnoid hemorrhage in rabbit.
  29. Guang Liu,Zheng Wang,Yun Wang,Li Xu,Xiao Wang,Yong Liu,Guo Luo,Guo He,Yan Zeng (2012). Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage.
  30. Fabio Taccone,Diego Castanares-Zapatero,Daliana Peres-Bota,Jean-Louis Vincent,Jacques Berre’,Christian Melot (2010). Cerebral Autoregulation is Influenced by Carbon Dioxide Levels in Patients with Septic Shock.
  31. W Van Den Bergh,R Dijkhuizen,G Rinkel (2004). Potentials of magnesium treatment in subarachnoid haemorrhage.
  32. S Ortega-Gutierrez,S Mayer (2010). Is the magnesium era for aneurysmal subarachnoid hemorrhage over?.
  33. Michael Diringer,Thomas Bleck,J Claude Hemphill,David Menon,Lori Shutter,Paul Vespa,Nicolas Bruder,E Connolly,Giuseppe Citerio,Daryl Gress,Daniel Hänggi,Brian Hoh,Giuseppe Lanzino,Peter Le Roux,Alejandro Rabinstein,Erich Schmutzhard,Nino Stocchetti,Jose Suarez,Miriam Treggiari,Ming-Yuan Tseng,Mervyn Vergouwen,Stefan Wolf,Gregory Zipfel (2011). Critical Care Management of Patients Following Aneurysmal Subarachnoid Hemorrhage: Recommendations from the Neurocritical Care Society’s Multidisciplinary Consensus Conference.
  34. Walter Van Den Bergh,A Algra,F Van Kooten,C Dirven,J Van Gijn,M Vermeulen (2005). Magnesium Sulfate in Aneurysmal Subarachnoid Hemorrhage.
  35. E Golan,D Vasquez,N Ferguson,Nkj Adhikari,D Scales (2013). Prophylactic magnesium for improving neurologic outcome after aneurysmal subarachnoid hemorrhage: Systematic review and meta-analysis.
  36. C Bradford,S Finfer,O' Connor,A Yarad,E Firth,R Mccallister,R (2013). A randomised controlled trial of induced hypermagnesaemia following aneurysmal subarachnoid haemorrhage.
  37. T Yamamoto,K Mori,T Esaki,Y Nakao,J Tokugawa,M Watanabe (2015). Preventive effect of continuous cisternal irrigation with magnesium sulfate solution on angiographic cerebral vasospasms associated with aneurismal subarachnoid hemorrhages: a randomized controlled trial.
  38. A Endo,M Kuroda,K Tanzawa (1976). Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme a reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity.
  39. Cynthia Bautista (2012). Unresolved Issues in the Management of Aneurysmal Subarachnoid Hemorrhage.
  40. Masaru Yamada,Zhihong Huang,Turgay Dalkara,Matthias Endres,Ulrich Laufs,Christian Waeber,Paul Huang,James Liao,Michael Moskowitz (2000). Endothelial Nitric Oxide Synthase-Dependent Cerebral Blood Flow Augmentation by <scp>L</scp>-Arginine After Chronic Statin Treatment.
  41. M Vergouwen,R De Haan,M Vermeulen,Y Roos (2010). Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis update.
  42. K Garg,S Sinha,S Kale,P Chandra,A Suri,M Singh,R Kumar,M Sharma,R Pandey,B Sharma,A Mahapatra (2013). Role of simvastatin in prevention of vasospasm and improving functional outcome after aneurysmal sub-arachnoid hemorrhage: a prospective, randomized, double-blind, placebo-controlled pilot trial.
  43. S Su,W Xu,J Hai,Y Wu,F Yu (2014). Effects of statinsuse for patients with aneurysmal subarachnoid after aneurysmal subarachnoid hemorrhage.
  44. I Siasios,E Kapsalaki,K Fountas (2013). Cerebral vasospasm pharmacological treatment: An update.
  45. Hartmut Vatter,Michael Zimmermann,Veronika Tesanovic,Andreas Raabe,Lothar Schilling,Volker Seifert (2005). Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: Inhibitory effect on endothelinA receptor—mediated contraction.
  46. G Povlsen,L Edvinsson (2015). MEK1/2 inhibitor U0126 but not endothelin receptor antagonist clazosentan reduces upregulation of cerebrovascular contractile receptors and delayed cerebral ischemia, and improves outcome after subarachnoid hemorrhage in rats.
  47. Xiang Wang,Yi-Ming Li,Wei-Qing Li,Cheng-Guang Huang,Yi-Cheng Lu,Li-Jun Hou (2012). Effect of Clazosentan in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized Controlled Trials.
  48. J Shen,J Pan,Z Fan,X Xiong,R Zhan (2013). Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: A metaanalysis of randomized controlled trials.
  49. R Macdonald,R Higashida,E Keller,S Mayer,A Molyneux,A Raabe (2013). Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).
  50. H Kim,G Britton,T Peng,C Holland,D Mcpherson,S Huang (2014). Nitric oxide-loaded echogenic liposomes for treatment of vasospasm following subarachnoid hemorrhage.
  51. Ali Fathi,Kamran Bakhtian,Ryszard Pluta (2011). The Role of Nitric Oxide Donors in Treating Cerebral Vasospasm After Subarachnoid Hemorrhage.
  52. Richard Clatterbuck,Philippe Gailloud,Travis Tierney,Victoria Clatterbuck,Kieran Murphy,Rafael Tamargo (2005). Controlled release of a nitric oxide donor for the prevention of delayed cerebral vasospasm following experimental subarachnoid hemorrhage in nonhuman primates.
  53. P Garry,M Ezra,M Rowland,J Westbrook,Kts Pattinson (2015). The role of the nitric oxide pathway in brain injury and its treatment -From bench to bedside.
  54. Fatima Sehba,Amit Schwartz,Igor Chereshnev,Joshua Bederson (2000). Acute Decrease in Cerebral Nitric Oxide Levels after Subarachnoid Hemorrhage.
  55. Rafael Radi (2013). Peroxynitrite, a Stealthy Biological Oxidant.
  56. J Simard,E Aldrich,David Schreibman,Robert James,Adam Polifka,Narlin Beaty (2013). Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.
  57. G Wurm,B Tomancok,K Nussbaumer,C Adelwöhrer,K Holl (2004). Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a doubleblind, randomizedcomparison of enoxaparin versus placebo.
  58. T Yamamoto,T Esaki,Y Nakao,K Mori (2010). Efficacy of low-dose tissue-plasminogen activator intracisternal administration for the prevention of cerebral vasospasm after subarachnoid hemorrhage.
  59. N Etminan,K Beseoglu,S Eicker,B Turowski,H Steiger,D Hänggi (2013). Prospective, randomized, open-label phase II trial on concomitant intraventricular fibrinolysis and low-frequencyrotation after severe subarachnoid hemorrhage.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Yong-Fei Liu. 2016. \u201cDrug Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage Following Aneurysms\u201d. Global Journal of Medical Research - A: Neurology & Nervous System GJMR-A Volume 16 (GJMR Volume 16 Issue A1): .

Download Citation

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-A Classification: NLMC Code: R743.35
Version of record

v1.2

Issue date

July 15, 2016

Language
en
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 3562
Total Downloads: 1828
2026 Trends
Related Research

Published Article

Cerebral vasospasm (CVS) is a common and severe complication of aneurysmal subarachnoid hemorrhage (aSAH). Despite the improvement in treatment of aSAH, CVS complicating aSAH has remained the main cause of death. CVS begins most often on the third day after the ictal event and reaches the maximum on the 5th-7th postictal days. Several therapeutic modalities have been employed to prevent or reverse CVS. The aim of this review is to emphatically introduce some kind of pharmacological agent for vasospasm.

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

Quote and Order Details

Contact Person

Invoice Address

Notes or Comments

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Drug Treatment of Cerebral Vasospasm after Subarachnoid Hemorrhage Following Aneurysms

Yong-Fei Liu
Yong-Fei Liu Army Medical University
Han-Cheng Qiu
Han-Cheng Qiu
Juan Su
Juan Su
Wei-Jian Jiang
Wei-Jian Jiang

Research Journals